Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 3,920,000 shares, an increase of 39.0% from the September 30th total of 2,820,000 shares. Currently, 8.2% of the company’s shares are sold short. Based on an average daily trading volume, of 3,290,000 shares, the short-interest ratio is currently 1.2 days. Based on an average daily trading volume, of 3,290,000 shares, the short-interest ratio is currently 1.2 days. Currently, 8.2% of the company’s shares are sold short.

Moleculin Biotech Stock Down 6.5%

Shares of NASDAQ MBRX traded down $0.03 during trading hours on Tuesday, hitting $0.49. 1,893,782 shares of the stock were exchanged, compared to its average volume of 4,461,516. The firm has a fifty day moving average price of $0.45 and a 200-day moving average price of $0.63. Moleculin Biotech has a 12 month low of $0.25 and a 12 month high of $3.65. The company has a market cap of $24.06 million, a PE ratio of -0.15 and a beta of 1.57.

Moleculin Biotech (NASDAQ:MBRX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts anticipate that Moleculin Biotech will post -7.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MBRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Moleculin Biotech in a report on Wednesday, September 10th. Finally, Wall Street Zen cut Moleculin Biotech to a “strong sell” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC increased its stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,250,000 shares of the company’s stock after acquiring an additional 932,414 shares during the period. Armistice Capital LLC owned about 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.